Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

The 2027 GOLD report for COPD management introduces new clinical updates, though it highlights a gap between emerging biologic treatments and current regulatory approvals. Expert Dave Singh discusses the implications of these findings for clinicians managing respiratory diseases.
Why it matters
Updates to global medical guidelines directly influence how millions of patients with chronic respiratory conditions are treated worldwide.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) presented its 2027 report at the GOLD 2026 COPD International Conference in Philadelphia, where Alvar Agustí, MD, and Claus F. Vogelmeier, MD, reviewed the annual update to its global strategy related to COPD diagnosis, management, and prevention.¹
The update comes about as late-stage biologic data outpace regulatory approval. Tozorakimab, an anti-interleukin (IL)-33 monoclonal antibody, reduced annualized moderate to severe exacerbations among former smokers by 29% and 34% compared with placebo in the replicate phase 3 OBERON and TITANIA trials, published in The New England Journal of Medicine.²
Results for astegolimab, an anti-ST2 monoclonal antibody blocking IL-33 signaling, were mixed. The phase 2b ALIENTO trial met its primary end point with a 15.4% reduction in annualized exacerbation rate, while the phase 3 ARNASA trial showed a numerical 14.5% reduction without statistical significance, according to Roche.³
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in